JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) but lowers the price target from $45 to $43.
August 07, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Protagonist Therapeutics but lowers the price target from $45 to $43.
The Market Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100